Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Briacell Therapeutics Corp BCTXW


Primary Symbol: T.BCT Alternate Symbol(s):  BCTX

Healthcare Biotechnology
BriaCell Therapeutics Corp. is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. Bria-IMT, its Phase 3 lead candidate, is a patented, off-the-shelf, cell-based, targeted immunotherapy that activates the patient’s immune system to specifically kill cancer cells without harming other cells. The Company is advancing its Bria-IMT targeted... see more

Recent & Breaking News (TSX:BCT)

BriaCell Reports Positive Breast Cancer Efficacy Data with Bria-IMT(TM) Immunotherapy Treatment at SITC Annual Meeting

GlobeNewswire November 10, 2022

BriaCell (TSX:BCT) completes Phase I of its clinical study in advanced breast cancer

Brieanna McCutcheon  October 21, 2022

BriaCell Announces Successful Completion of Phase I Portion of Clinical Study in Advanced Breast Cancer; Randomized Phase II Efficacy Evaluation Progressing

GlobeNewswire October 21, 2022

BriaCell (TSX:BCT) works towards new clinical trial site

Brieanna McCutcheon  October 12, 2022

BriaCell Announces New Clinical Trial Site to Bring Novel Cancer Treatments to Advanced Breast Cancer Patients

GlobeNewswire October 12, 2022

BriaCell to Present New Clinical Data at the 2022 San Antonio Breast Cancer Symposium® December 6th and 7th

GlobeNewswire September 28, 2022

BriaCell (TSX:BCT) partners with Caris Life Sciences to expand patient outreach and molecular profiling

Azuka Onwuka September 14, 2022

BriaCell Partners with Caris Life Sciences® to Expand Patient Outreach and Molecular Profiling

GlobeNewswire September 14, 2022

BriaCell Announces Presentation at the 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting

GlobeNewswire September 7, 2022

BriaCell (TSX:BCT) secures licence for a promising novel anti-cancer agent

Azuka Onwuka August 4, 2022

BriaCell Secures License for a Promising Novel Anti-Cancer Agent

GlobeNewswire August 4, 2022

BriaCell (TSX:BCT) partners with Waisman Biomanufacturing

Shoran Devi July 5, 2022

BriaCell Partners with Waisman Biomanufacturing to Manufacture and Supply Prostate Cancer Immunotherapy

GlobeNewswire July 5, 2022

BriaCell (TSX:BCT) signs research agreement to identify novel targets for cancer treatment

Azuka Onwuka June 29, 2022

BriaCell Enters Research Agreement to Identify Novel Targets for Cancer Treatment

GlobeNewswire June 29, 2022

Leading cancer drug discovery journal highlights BriaCell (TSX:BCT) technology

Jonathon Brown June 24, 2022

BriaCell Anti-Cancer Technology Published in Leading Cancer Drug Discovery Journal

GlobeNewswire June 24, 2022

BriaCell Adds Additional Clinical Sites to Broaden Patient Access and Further Boost Enrollment

GlobeNewswire May 18, 2022

BriaCell Receives FDA Fast Track Approval for Targeted Breast Cancer Immunotherapy

GlobeNewswire April 13, 2022

BriaCell (TSX:BCT) receives FDA Fast Track approval for targeted breast cancer immunotherapy

Brieanna McCutcheon  April 13, 2022